LBRX — LB Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $517.11m
- $202.63m
- 14
- 39
- 83
- 42
Annual cashflow statement for LB Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS |
| Standards: | USG | USG |
| Status: | Final | Final |
| Net Income/Starting Line | -6.28 | -63.1 |
| Depreciation | ||
| Non-Cash Items | -4.51 | 6.65 |
| Unusual Items | ||
| Other Non-Cash Items | ||
| Changes in Working Capital | -1.31 | 3.31 |
| Change in Prepaid Expenses | ||
| Change in Accrued Expenses | ||
| Change in Payable / Accrued Expenses | ||
| Cash from Operating Activities | -12.1 | -53.1 |
| Capital Expenditures | -0.025 | -0.769 |
| Purchase of Fixed Assets | ||
| Other Investing Cash Flow Items | -28 | 24 |
| Sale/Maturity of Investment | ||
| Purchase of Investments | ||
| Cash from Investing Activities | -28 | 23.2 |
| Financing Cash Flow Items | -0.089 | 0 |
| Other Financing Cash Flow | ||
| Net Issuance / Retirement of Stock | ||
| Net Issuance / Retirement of Debt | ||
| Cash from Financing Activities | 33.7 | 38.3 |
| Beginning Cash Balance | ||
| Ending Cash Balance | ||
| Net Change in Cash | -6.42 | 8.5 |